

Migraine

CHI Formulary Treatment algorithm

Treatment algorithm- October 2023

Supporting treatment algorithms for the clinical management of Migraine

Figure 1 outlines a comprehensive treatment algorithm on **the management of Migraine**, aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

For further evidence, please refer to CHI **Migraine** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx

Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.

Pharmacological Prevention of Migraine

Indication: level of suffering, Improvement of quality of Life

Principles of prevenve treatment-Clarify in advance:

- Efficacy (reduction of headaches by approx. 50%, delayed onset of action)
- Side effects (detailed informaon for chosen drug, side effects oen early in dosing)-

"start low go slow"

- -Therapy monitoring (Headache diary)
- -Therapy meframe(6-12 months, then check for necessity)
- -Therapy change/terminaon (If no sasfactory improvement within 2 months aer reaching the final dose)

Medications with Evidence of Efficacy in Migraine Prevention:

Oral:

andesartan Divalproex sodium

Frovatriptan Metoprolo Propranolol Timolol

Topiramate Valproate sodium

Parenteral:

Eptinezumab Erenumab

Fremanezumab Galcanezumab
Onahotulinumtoxin A

Figure 1: Treatment algorithm of Migraine

medical treatment:

- -Frequent aerobic endurance sports
- -Behavioural therapeuc procedures, e.g.:-relaxaon techniques
- -biofeedback
- -Psychological pain therapy, e.g.: pain management
- stress management
- -Cognive behavioural therapy, if necessary-Limitaon of acute medicaon to < 10/day per month

Parenteral:

Probably effective:

OnabotulinumtoxinA + CGRP mAb

Oral:

¹ The American Headache Society Consensus Statement: Update on Integrating New Migraine Treatments into Clinical Practice (2021)